Price$7.20-0.15 (-2.04%)
01:30 PM07:45 PM
News · 26 weeks34-43%
2025-10-262026-04-19
Mix2290d
- Insider8(36%)
- Other5(23%)
- SEC Filings5(23%)
- Earnings3(14%)
- Analyst1(5%)
Latest news
25 items- PRRxSight, Inc. to Report First Quarter 2026 Financial Results on May 6ALISO VIEJO, Calif., April 22, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) – RxSight, Inc., today announced that it will report financial results for the first quarter after the market close on Wednesday, May 6, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 2630350. The call will also be broadcast live in listen-only mode via a link on the company's investor relations website at https://investors.rxsight.com/. An archived recording of the call will be available through the same link s
- INSIDERSEC Form 4 filed by Goldshleger Ilya4 - RxSight, Inc. (0001111485) (Issuer)
- PRRxSight Highlights 300,000 Light Adjustable Lens Implant Milestone and Strong Scientific Presence at ASCRS 2026WASHINGTON, April 08, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ:RXST) today announced, in advance of the 2026 American Society of Cataract and Refractive Surgery (ASCRS) annual meeting, that over 300,000 Light Adjustable Lens® (LAL®) implants have been performed since launch, marking a significant milestone in the company's pursuit to make customized vision correction widely available to patients. The RxSight® Light Adjustable Lens system is the first and only intraocular lens (IOL) technology that enables doctors to optimize a patient's vision after cataract surgery based on real-world visual feedback. "The 300,000 milestone is a testament to the skill and dedication of the doctors
- PRRxSight, Inc. to Participate in the 25th Annual Needham Virtual Healthcare ConferenceALISO VIEJO, Calif., April 02, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) RxSight, Inc., today announced plans to participate in the upcoming 25th Annual Needham Virtual Healthcare Conference. Management is scheduled to participate in a fireside chat on Thursday, April 16, 2026, at 8:00 a.m. Pacific Time. A live and archived webcast of the presentation will be available on the company's investor relations website at https://investors.rxsight.com/. About RxSight, Inc. RxSight, Inc. is an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery. The RxSight® Light Adjustable Lens system, comprised of the RxSight Light Adjust
- SECAmendment: SEC Form SCHEDULE 13G/A filed by RxSight Inc.SCHEDULE 13G/A - RxSight, Inc. (0001111485) (Subject)
- SECAmendment: SEC Form 8-K/A filed by RxSight Inc.8-K/A - RxSight, Inc. (0001111485) (Filer)
- INSIDERChief Financial Officer Wilterding Mark converted options into 20,441 shares and covered exercise/tax liability with 8,068 shares (SEC Form 4)4 - RxSight, Inc. (0001111485) (Issuer)
- INSIDERChief Customer Officer Gaines Scott converted options into 6,261 shares and covered exercise/tax liability with 2,580 shares, increasing direct ownership by 33% to 14,848 units (SEC Form 4)4 - RxSight, Inc. (0001111485) (Issuer)
- INSIDERSEC Form 4 filed by Chief Operating Officer Goldshleger Ilya4 - RxSight, Inc. (0001111485) (Issuer)
- INSIDERSEC Form 4 filed by Officer Weinberg Eric4 - RxSight, Inc. (0001111485) (Issuer)
- INSIDERSEC Form 4 filed by President & CEO Kurtz Ronald M Md4 - RxSight, Inc. (0001111485) (Issuer)
- SECSEC Form EFFECT filed by RxSight Inc.EFFECT - RxSight, Inc. (0001111485) (Filer)
- SECSEC Form POS AM filed by RxSight Inc.POS AM - RxSight, Inc. (0001111485) (Filer)
- SECSEC Form S-8 filed by RxSight Inc.S-8 - RxSight, Inc. (0001111485) (Filer)
- SECSEC Form 10-K filed by RxSight Inc.10-K - RxSight, Inc. (0001111485) (Filer)
- SECRxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits8-K - RxSight, Inc. (0001111485) (Filer)
- PRRXSight, Inc. Reports Fourth Quarter and 2025 Results; Issues 2026 GuidanceALISO VIEJO, Calif., Feb. 25, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc. (NASDAQ:RXST) today reported financial results for the quarter and full year ended December 31, 2025. Strategic Highlights and Recent Developments 2025 Light Adjustable Lens (LAL® and LAL+®) unit sales increased 12% to 109,615Over 300,000 RxSight LAL procedures performed since launch, reinforcing the benefits of post-operative adjustability in clinical practiceLight Delivery Devices (LDD™) installed base expanded to 1,134, providing a strong foundation for future procedure growthRxSight's FDA Post-approval study results, demonstrating statistically superior outcomes for LAL eyes compared to historical results from conte
- SECSEC Form POSASR filed by RxSight Inc.POSASR - RxSight, Inc. (0001111485) (Filer)
- PRRxSight, Inc. To Report Fourth Quarter and Full Year 2025 Financial Results on February 25, 2026ALISO VIEJO, Calif., Feb. 11, 2026 (GLOBE NEWSWIRE) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, will report financial results for the fourth quarter and full year 2025 after the market close on Wednesday, February 25, 2026. The company's management will discuss the results during a conference call beginning at 1:30 p.m. Pacific Time / 4:30 p.m. Eastern Time. To participate in the conference call, please dial (800) 715-9871 or (646) 307-1963, and enter the conference code: 3406720. The call will also be broadcast live in listen-only mode via a link on the company's investor relations we
- INSIDERSEC Form 4 filed by Chief Financial Officer Wilterding Mark4 - RxSight, Inc. (0001111485) (Issuer)
- INSIDERSEC Form 3 filed by new insider Wilterding Mark3 - RxSight, Inc. (0001111485) (Issuer)
- ANALYSTWilliam Blair initiated coverage on RxSightWilliam Blair initiated coverage of RxSight with a rating of Mkt Perform
- INSIDERNew insider Gaines Scott claimed ownership of 11,167 shares (SEC Form 3)3 - RxSight, Inc. (0001111485) (Issuer)
- SECRxSight Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits8-K - RxSight, Inc. (0001111485) (Filer)
- PRRxSight, Inc. Announces Preliminary Q4 and 2025 Financial Results; New Chief Financial OfficerALISO VIEJO, Calif., Jan. 11, 2026 (GLOBE NEWSWIRE) -- (NASDAQ:RXST) -- RxSight, Inc., an ophthalmic medical device company dedicated to providing high-quality customized vision to patients following cataract surgery, today announced certain preliminary unaudited financial and operational results for the fourth quarter and full-year 2025. In addition, the company provided an update on the previously announced Chief Financial Officer transition. Preliminary Unaudited Fourth Quarter and Full-year 2025 Results Preliminary unaudited fourth quarter 2025 revenue is expected to be approximately $32.6 million, driven by: The sale of 28,611 Light Adjustable Lenses (LAL™/LAL+®); representing a 10